Literature DB >> 10847128

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

.   

Abstract

Hepatitis C is a global health problem caused by infection with the hepatitis C virus. Although representative prevalence data are not available from many countries, available data indicate that approximately 3% of the world's population is infected with HCV. It is estimated that as many as 170 million persons world-wide may be infected with HCV. In many countries, the exact magnitude of the problem and the relative contribution of the various routes of transmission have not been defined with population-based studies. Wherever possible such studies should be performed to enable countries to estimate the burden of hepatitis C disease, to prioritize their preventative measures and to make the most appropriate use of available resources. To assess hepatitis C on a global scale, the World Health Organization (WHO) organized a consultation of international experts, in order to review the public health aspects related to hepatitis C infection and to make recommendations for its prevention and control.

Entities:  

Mesh:

Year:  1999        PMID: 10847128

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  246 in total

1.  Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain.

Authors:  G Barbato; D O Cicero; F Cordier; F Narjes; B Gerlach; S Sambucini; S Grzesiek; V G Matassa; R De Francesco; R Bazzo
Journal:  EMBO J       Date:  2000-03-15       Impact factor: 11.598

2.  Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C.

Authors:  L Kleinman; M W Zodet; Z Hakim; J Aledort; C Barker; K Chan; L Krupp; D Revicki
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

Review 3.  Current status of hepatitis C in Canada.

Authors:  S Zou; M Tepper; A Giulivi
Journal:  Can J Public Health       Date:  2000 Jul-Aug

4.  Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept.

Authors:  C Leboeuf; J Roser-Schilder; M Lambotin; S Durand; T Wu; C Fauvelle; B Su; E Bôle-Richard; M Deschamps; C Ferrand; P Tiberghien; P Pessaux; T F Baumert; E Robinet
Journal:  Gene Ther       Date:  2014-11-13       Impact factor: 5.250

5.  Hepatitis C virus treatment complicated by rheumatoid arthritis.

Authors:  Meredith Borman; Mark G Swain
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

6.  High prevalence of non-organ-specific autoantibodies in hepatitis C virus-infected cirrhotic patients from southern Italy.

Authors:  Giovanni Squadrito; Marcello Previti; Marco Lenzi; Enrico Pagano Le Rose; Gaia Caccamo; Tea Restuccia; Enrico Di Cesare; Teresa Pollicino; Giovanni Raimondo
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

Review 7.  Viral hepatitis: new data on hepatitis C infection.

Authors:  Erzsébet Szabó; Gábor Lotz; Csilla Páska; András Kiss; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2003-12-22       Impact factor: 3.201

8.  Soluble receptor for advanced glycation end products and risk of liver cancer.

Authors:  Kristin A Moy; Li Jiao; Neal D Freedman; Stephanie J Weinstein; Rashmi Sinha; Jarmo Virtamo; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

9.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Genetic analysis of the carboxy-terminal region of the hepatitis C virus core protein.

Authors:  Martina Kopp; Catherine L Murray; Christopher T Jones; Charles M Rice
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.